Long-term cardiovascular disease risk after anthracycline and trastuzumab treatments in U.S. breast cancer survivors.
Vo JB, Ramin C, Veiga LHS, Brandt C, Curtis RE, Bodelon C, Barac A, Roger VL, Feigelson HS, Buist DSM, Bowles EJA, Gierach GL, Berrington de González A.
Vo JB, et al. Among authors: brandt c.
J Natl Cancer Inst. 2024 May 8:djae107. doi: 10.1093/jnci/djae107. Online ahead of print.
J Natl Cancer Inst. 2024.
PMID: 38718210